Who Paid My Doc
A Phase 2, Randomized, Double-Blind, Multi-Dose, Dose Finding Study to
Research payments
$4,188,654
Through program year 2025, $4,188,654 in research payments was reported against A Phase 2, Randomized, Double-Blind, Multi-Dose, Dose Finding Study to, across 622 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $1,824,444 | 397 |
| 2024 | Research | $1,617,152 | 147 |
| 2023 | Research | $702,781 | 64 |
| 2022 | Research | $44,277 | 14 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Kashif Ali Houston, TX Named on 31 payments
- Gysella Muniz Pujalt Pittsburgh, PA Named on 23 payments
- Scott Dobson Greenville, SC Named on 21 payments
- Odette Olivieri Ramos Ponce, PR Named on 18 payments
- Merlin Fausett Missoula, MT Named on 18 payments
- Jibran Atwi Lake Charles, LA Named on 17 payments
- Jose Diaz Los Angeles, CA Named on 15 payments
- Randall Reese Gulf Breeze, FL Named on 15 payments
- Daniel Leonard Grand Island, NE Named on 14 payments
- Amarnath Chamkur Cypress, TX Named on 13 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.